The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. The result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.
Efficacy evaluation is critical for understanding the practical application effect of telehealth integrated mode in the therapy of cardiometabolic disease patients. We can comprehend the influence of the combination of online and offline models on patients' clinical curative effect, medication compliance, medical cost, and satisfaction by analyzing the curative effect and finding a scientific basis for clinical practice and policy formation. As a result, the purpose of this study is to assess the curative effect of hyperlipidemia patients with other cardiometabolic disease using a telehealth integrated model, as well as to investigate the potential benefits and risks of this model in the management of cardiometabolic disease.
Study Type
OBSERVATIONAL
Enrollment
1,302
Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
Peking University Third Hospital
Beijing, Beijing Municipality, China
RECRUITINGchanges of compliance rate of target treatment for hyperlipidemia
difference of compliance rate of target treatment for hyperlipidemia between endpoint with baseline
Time frame: 12 month after recuitment
changes of blood pressure
difference of blood pressure（both systolic and diastolic blood pressure will be measured.） between endpoint with baseline
Time frame: 12 month after recuitment
changes of glycosylated hemoglobin
difference of glycosylated hemoglobin between endpoint with baseline
Time frame: 12 month after recuitment
changes of fasting glucose
difference of fasting glucose between endpoint with baseline
Time frame: 12 month after recuitment
changes of LDL-c
difference of LDL-c between endpoint with baseline
Time frame: 12 month after recuitment
changes of triglyceride
difference of triglyceride between endpoint with baseline
Time frame: 12 month after recuitment
abnormal liver function
an increase above the 3-fold normal value for ALT or AST.
Time frame: 12 month after recuitment
abnormal kidney function
an increase in creatinine of ≥ 30%
Time frame: 12 month after recuitment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rehospitalization
Rehospitalization because of coronary heart disease, poor blood pressure control, and poor glycemic control
Time frame: 12 month
Cardiovascular death
Death because of cardiovascular diseases and sudden death
Time frame: 12 month
medication adherence rate
Difference of medication adherence between each group measured by Morisky Medication Adherence Scale-8
Time frame: 12 month
patients satisfaction
patients will be asked to rate their satisfaction score in Likert form with 1 being the most unsatisfactory and 5 being the most satisfactory on the overall experience, the medical diagnosis process, service attitude and physician's professionalism.
Time frame: 12 month
medical cost
Health Economics on medical cost, transportation cost, accommodation cost, waiting time and lost work time
Time frame: 12 month
in person visit counts
total number of in person visits
Time frame: 12 month after recuitment
telehealth visit counts
total number of telehealth visits
Time frame: 12 month after recuitment